The Key Clinical Questions of Neoadjuvant Chemoradiotherapy for Resectable Esophageal Cancer—A Review

Over 50% of individuals with esophageal cancer (EC) present with advanced stages of the disease; therefore, their outcome following surgery alone is poor, with only 25%–36% being alive 5 years post-surgery. Based on the evidence that the CROSS and NEOCRTEC5010 trials provided, neoadjuvant chemoradio...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Dan Han, Baosheng Li, Qian Zhao, Hongfu Sun, Jinling Dong, Shaoyu Hao, Wei Huang
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Frontiers Media S.A. 2022-07-01
Serie:	Frontiers in Oncology
Soggetti:	esophageal cancer neoadjuvant chemoradiotherapy neoadjuvant immunotherapy pathological complete remission (pCR) target volume delineation
Accesso online:	https://www.frontiersin.org/articles/10.3389/fonc.2022.890688/full
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!